Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is secretory carcinoma (salivary gland)?
Secretory carcinoma is a type of salivary-gland cancer that was only recognized in the last decade or so. It was previously confused with another salivary cancer (acinic cell carcinoma) until researchers discovered it has its own distinctive gene fusion — most often ETV6-NTRK3, the same NTRK fusion found in some other rare cancers. It usually arises in the parotid gland (the large salivary gland in front of the ear) or in smaller glands of the mouth, and it can also occur in the breast, where it is called secretory (or mammary analogue) carcinoma. Most cases are slow-growing and low-grade with a good outlook, treated with surgery and sometimes radiation. The discovery of the NTRK fusion is important because targeted NTRK-inhibitor pills can dramatically shrink the cancer in the uncommon cases that become advanced.
The main types
Doctors group secretory carcinoma (salivary gland) by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Salivary secretory carcinoma | The usual form, arising in the parotid or other salivary glands; mostly low-grade and slow-growing, defined by the ETV6-NTRK3 gene fusion. |
| High-grade transformed secretory carcinoma | An uncommon, more aggressive version that has changed to a higher grade; it carries a greater risk of node and distant spread and needs more intensive treatment. |
Staging, in plain terms
Secretory carcinoma is staged with the TNM system for salivary-gland cancers — the size and reach of the tumor (T), spread to neck lymph nodes (N), and spread to distant organs (M) — combined with its grade. Because most cases are low-grade and caught early, they fall into earlier stages with an excellent outlook. The uncommon high-grade or 'transformed' tumors are staged the same way but behave more aggressively and are treated more intensively.
| Head-and-neck (salivary) TNM + grade | What it generally means |
|---|---|
| Early, low-grade | A small tumor confined to the gland. Usually cured with surgery alone, with an excellent long-term outlook. |
| Larger or node-positive | A bigger tumor or spread to neck lymph nodes. Treated with surgery plus radiation to the area and neck to improve control. |
| High-grade or metastatic | Aggressive or distant disease. Treated with surgery and radiation where possible, and — because of the NTRK fusion — with a targeted NTRK-inhibitor pill that can shrink widespread cancer. |
The standard of care
Secretory Carcinoma (Salivary Gland) is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery (the main treatment)
Removing the tumor — for example, removing part or all of the parotid gland while protecting the facial nerve — is the primary treatment and often cures early, low-grade disease.
Radiation therapy
Radiation is added after surgery for larger tumors, close or positive margins, nerve involvement, or lymph-node spread, and it can be the main treatment when surgery is not possible.
Targeted NTRK-inhibitor therapy
For advanced or metastatic disease, pills that block the NTRK fusion protein (such as larotrectinib or entrectinib) can produce strong, lasting responses — a major advantage of identifying the fusion.
Neck evaluation and follow-up
The neck lymph nodes are checked and treated when needed, and patients are followed over time because, although most do very well, the cancer can occasionally recur.
How radiation treatment works
Radiation damages the DNA inside cancer cells so they can no longer divide. For secretory carcinoma, surgery is usually the main treatment, but radiation is an important partner after surgery when the tumor is large, the margins are close, a nerve is involved, or lymph nodes are affected — it treats the microscopic cells left behind and lowers the chance of the cancer returning. Intensity-modulated radiation shapes the dose around the salivary region and neck while sparing healthy glands and swallowing muscles to limit dry mouth and other side effects. Radiation is painless during delivery, given over several weeks of daily sessions, and external-beam treatment leaves no radioactivity in the body.
The main ways radiation is delivered for secretory carcinoma (salivary gland):
Intensity-modulated radiation (IMRT)
Beams are shaped around the salivary region and neck to treat the tumor bed while sparing the other salivary glands, swallowing muscles, and jaw.
Proton therapy (selected)
Protons can reduce dose to nearby structures for tumors near the skull base or when re-treating an area, lowering side effects.
Neutron / particle therapy (selected high-grade)
For certain aggressive salivary cancers that resist standard radiation, specialized particle beams at expert centers can improve local control.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
A new cancer defined by its gene fusion: Researchers showed that many tumors once called acinic cell carcinoma are actually a distinct entity driven by the ETV6-NTRK3 fusion, leading to recognition of secretory carcinoma as its own diagnosis.[1]
American Journal of Surgical Pathology (Skalova et al.) and WHO salivary tumor classification
Targeted NTRK therapy for advanced disease: Trials of NTRK inhibitors (larotrectinib, entrectinib) reported high and durable response rates in NTRK-fusion cancers, including advanced secretory carcinoma, supporting fusion testing to open this treatment option.[2]
New England Journal of Medicine / Lancet Oncology NTRK-inhibitor trials
Generally favorable outcomes: Clinical series confirm most salivary secretory carcinomas are low-grade with excellent outcomes after surgery, with radiation reserved for higher-risk features and rare high-grade transformation requiring more intensive care.[3]
Head & Neck / Oral Oncology outcome series
Common questions
How is this different from acinic cell carcinoma? For years secretory carcinoma was grouped with acinic cell carcinoma because they look similar. Researchers then found that secretory carcinoma has its own gene fusion (ETV6-NTRK3). Telling them apart matters because the fusion makes targeted NTRK-inhibitor pills an option for advanced secretory carcinoma.
Is it usually serious? Most secretory carcinomas are low-grade and slow-growing, with an excellent outlook after surgery. A minority are high-grade or 'transformed' and behave more aggressively, needing surgery, radiation, and close follow-up. Your team will base the plan on your tumor's grade and stage.
Why does testing for the NTRK fusion matter? Finding the ETV6-NTRK3 fusion confirms the diagnosis and, importantly, identifies a treatment: in the uncommon cases that spread, NTRK-inhibitor pills can shrink the cancer significantly and for a long time. That makes molecular testing a valuable step, especially for advanced disease.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- American Journal of Surgical Pathology (Skalova et al.) and WHO salivary tumor classification (no indexed identifier — see your care team) ↩
- New England Journal of Medicine / Lancet Oncology NTRK-inhibitor trials (no indexed identifier — see your care team) ↩
- Head & Neck / Oral Oncology outcome series (no indexed identifier — see your care team) ↩